We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
Read MoreHide Full Article
Harrow Health (HROW - Free Report) shares ended the last trading session 17.8% higher at $21.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.4% loss over the past four weeks.
Harrow scored a strong price rise, driven by optimism surrounding the company’s recent announcement to acquire Japanese pharmaceutical company, Santen’s branded ophthalmic portfolio.
The addition of several high utility and trusted products positions the company’s portfolio to be one of the most comprehensive in the domestic market. The acquisition advances Harrow’s goal of becoming a leader in the top tier of ophthalmic pharmaceutical companies in United States, which might have boosted confidence in the stock.
This pharmaceutical and drug compounding company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of -200%. Revenues are expected to be $29.32 million, up 25.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Harrow, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on HROW going forward to see if this recent jump can turn into more strength down the road.
Harrow is a member of the Zacks Medical Services industry. One other stock in the same industry, Progyny (PGNY - Free Report) , finished the last trading session 0.7% lower at $40.22. PGNY has returned 4.9% over the past month.
Progyny's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.10. Compared to the company's year-ago EPS, this represents a change of +11.1%. Progyny currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
Harrow Health (HROW - Free Report) shares ended the last trading session 17.8% higher at $21.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.4% loss over the past four weeks.
Harrow scored a strong price rise, driven by optimism surrounding the company’s recent announcement to acquire Japanese pharmaceutical company, Santen’s branded ophthalmic portfolio.
The addition of several high utility and trusted products positions the company’s portfolio to be one of the most comprehensive in the domestic market. The acquisition advances Harrow’s goal of becoming a leader in the top tier of ophthalmic pharmaceutical companies in United States, which might have boosted confidence in the stock.
This pharmaceutical and drug compounding company is expected to post quarterly loss of $0.01 per share in its upcoming report, which represents a year-over-year change of -200%. Revenues are expected to be $29.32 million, up 25.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Harrow, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on HROW going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Harrow is a member of the Zacks Medical Services industry. One other stock in the same industry, Progyny (PGNY - Free Report) , finished the last trading session 0.7% lower at $40.22. PGNY has returned 4.9% over the past month.
Progyny's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.10. Compared to the company's year-ago EPS, this represents a change of +11.1%. Progyny currently boasts a Zacks Rank of #3 (Hold).